Gyre Therapeutics and March Biosciences: Advancements in CAR-T Cell Therapy Manufacturing
- March Biosciences received a $200,000 G-Rex Grant to improve manufacturing of its CAR-T therapy, MB-105.
- The grant aims to enhance scalability and efficiency in producing CAR-T therapies for T-cell lymphomas.
- March Biosciences' MB-105 also received FDA orphan drug designation, highlighting its potential in treating specific hematologic malignancies.
Advancements in CAR-T Cell Therapy Manufacturing: March Biosciences Receives G-Rex Grant
In a significant development for the field of cell and gene therapies, March Biosciences has been awarded a $200,000 G-Rex® Grant to enhance the manufacturing of its investigational autologous CAR-T cell therapy, MB-105. This therapy targets CD5 and is aimed at patients suffering from T-cell lymphomas. The grant, established by ScaleReady in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, is designed to address the scalability challenges often faced in the clinical manufacturing of CAR-T therapies. Dr. Maksim Mamonkin, the Chief Scientific Officer of March Biosciences, underscores that the funding will help implement robust current Good Manufacturing Practice (cGMP) processes, ultimately leading to a more efficient and cost-effective production pipeline.
The G-Rex bioreactor technology, co-invented by Wilson Wolf's CEO John Wilson, is central to this initiative. Wilson expresses optimism that the G-Rex Grant will facilitate the development of a streamlined CAR-T cell manufacturing process, which not only enhances the scalability of MB-105 but also positions March Biosciences to advance other pipeline products. With the increasing demand for CAR-T therapies, the ability to efficiently manufacture these products is crucial for bringing innovative treatments to market. The grant also expands upon the recent U.S. FDA orphan drug designation received by March Biosciences for MB-105, highlighting the therapy's potential in treating relapsed/refractory CD5-positive T-cell lymphoma and other hematologic malignancies.
ScaleReady's G-Rex Grant Program has a history of supporting advancements in cell and gene-modified cell therapy development, having issued nearly 200 grants to date. Each award, valued up to $300,000, not only provides financial support but also grants recipients access to a consortium of partners with expertise in cGMP manufacturing and regulatory affairs. This collaborative approach is expected to foster innovation and efficiency in the field, ultimately benefiting both companies like March Biosciences and the patients who will benefit from their therapies.
In a related sector, Continuity Biosciences has made a strategic investment in PinPrint, a company specializing in high-resolution 3D-printed microneedle technology. This collaboration aims to enhance drug delivery systems, particularly for vaccines and therapeutic agents, aligning with the industry's trend toward precision medicine. Meanwhile, GreenLight Biosciences announces its breakthrough in RNA-based bioherbicides, setting new standards for weed management and further diversifying its product offerings in agricultural biotechnology. These advancements reflect a dynamic shift toward innovative solutions across the health and life sciences sectors.
